Milea Timbergen

212 Supplementary Table 5. (continued) Kim et al. 43 (2016), Oncology Letters Salas et al. 49 (2010), Genes, Chromosomes & Cancer Nishida et al. 42 (2016), Oncology Letters Mullen et al. 20 (2013), The Oncologist Mussi et al. 41 (2016), Tumori Broekhoven et al. 22 (2015), Annals of Surgical Oncology Colombo et al. 23 (2013), Cancer Resection margin status R0 65 (54%) NS NS 52 (45%) 24 (80%) 64 (63%) 98 (55%) R1 56 (46%) NS NS 63 (55%) 3 (10%) 32 (32%) 68 (41%) Unknown - NS 13 (100%) 0 3 (10%) 5 (5%) 13 (4%) NS, not specified; ST, systemic treatment; A ST, adjuvant ST; Rtx, radiotherapy; CGH, comparative genomic hybridization; FFPE, formalin fixed, paraffin embedded, FT, frozen tissue a mean age (range); b median age (range); c median age [IQR]; d stated as ‘abdominal’; e out of 182 samples; f median follow-up (range); g median follow-up, no range provided; h mean follow-up (range); i median follow-up [IQR]; j abdominal and chest wall; k treatment data was extracted from the publication. S45P CTNNB1 mutation was categorized as ‘other’ in this table Percentages may not add up to 100% due to rounding up of decimals 7